Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic mecapegfilgrastim after chemotherapy in lymphoma
ChiCTR2100048123Phase 4Completed
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in lymphoma and febrile neutropenia (FN), sponsored by Shanxi Cancer Hospital. Primary endpoint: Absolute neutrophil count (ANC). Started Jan 2018; status: completed.
02
Drugs
mecapegfilgrastim
03
Conditions
lymphomafebrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR2100048123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048123.